STOCK TITAN

[Form 4] Outlook Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Outlook Therapeutics, Inc. director Huang Andong received two stock option grants totaling 340,050 options: 286,734 options at an exercise price of $1.04 (granted 10/01/2025) and 53,316 options at $1.06 (granted 10/03/2025). The larger grant is an annual non-employee director award under the company's 2024 Equity Incentive Plan and fully vests on October 1, 2026 subject to continuous service.

The smaller grant was issued in lieu of $50,000 of cash fees and vests in four equal quarterly installments, finishing on September 30, 2026, subject to continuous service. Both option grants include acceleration upon a defined Change in Control if the reporting person remains in service immediately prior to that event.

Outlook Therapeutics, Inc. direttore Huang Andong ha ricevuto due assegnazioni di stock option per un totale di 340.050 opzioni: 286.734 opzioni a un prezzo di esercizio di $1,04 (concesse il 01/10/2025) e 53.316 opzioni a $1,06 (concesse il 03/10/2025). La concessione maggiore è un premio annuale per direttore non dipendente ai sensi del piano azioni 2024 Equity Incentive Plan dell'azienda e si matura integralmente il 1 ottobre 2026, soggetto al servizio continuo. La concessione minore è stata emessa in sostituzione di $50.000 di compensi in contanti e matura in quattro rate trimestrali uguali, terminando il 30 settembre 2026, soggetto al servizio continuo. Entrambe le concessioni di opzioni includono accelerazione in caso di Cambio di Controllo definito se la persona che riferisce rimane in servizio immediatamente prima di tale evento.

Outlook Therapeutics, Inc. director Huang Andong recibió dos concesiones de opciones sobre acciones por un total de 340.050 opciones: 286.734 opciones a un precio de ejercicio de $1,04 (otorgadas el 01/10/2025) y 53.316 opciones a $1,06 (otorgadas el 03/10/2025). La concesión mayor es un premio anual para director no empleado bajo el 2024 Equity Incentive Plan de la empresa y se consolida por completo el 1 de octubre de 2026, sujeto a servicio continuo. La concesión menor fue emitida en sustitución de $50,000 en honorarios en efectivo y se consolida en cuatro cuotas trimestrales iguales, terminando el 30 de septiembre de 2026, sujeto a servicio continuo. Ambas concesiones de opciones incluyen aceleración ante un Cambio de Control definido si la persona que presenta el informe permanece en servicio inmediatamente antes de ese evento.

Outlook Therapeutics, Inc. 이사 Huang Andong은 총 340,050 주의 주식매수선택권을 받았으며, 그 중 286,734주는 실행가격 $1.04로, 2025-10-01에 수여되었습니다. 나머지 53,316주는 $1.06의 가격으로 2025-10-03에 수여되었습니다. 더 큰 수여는 회사의 2024 Equity Incentive Plan에 따른 연간 비근로 이사 보상에 해당하며, 지속적 서비스가 전제될 때 2026-10-01에 완전히 귀속됩니다. 소규모 수여는 현금 수수료 $50,000를 대신하여 발행되었고, 4개 분기 동안 매월 같은 비율로 귀속되며 2026-09-30에 종료됩니다. 두 주식매수선택권 모두 정의된 지배권 변화(Change in Control)가 발생할 경우, 해당 사건 직전까지 보고자가 재직 중이면 가속 귀속이 적용됩니다.

Outlook Therapeutics, Inc. directeur Huang Andong a reçu deux attributions d'options d'achat d'actions pour un total de 340.050 options: 286.734 options à un prix d'exercice de $1,04 (octroyées le 01/10/2025) et 53.316 options à $1,06 (octroyées le 03/10/2025). La plus grande attribution est une récompense annuelle pour directeur non salarié dans le cadre du Plan d'incitation en actions 2024 de l'entreprise et se consolide entièrement le 1er octobre 2026, sous réserve d'un service continu. La plus petite attribution a été émise en lieu et place de $50.000 de frais en espèces et se consolide en quatre versements trimestriels égaux, se terminant le 30 septembre 2026, sous réserve d'un service continu. Les deux attributions d'options prévoient une accélération en cas de changement de contrôle défini si la personne faisant rapport reste en poste immédiatement avant cet événement.

Outlook Therapeutics, Inc. Vorstand Huang Andong erhielt zwei Aktienoptionszuteilungen insgesamt 340.050 Optionen: 286.734 Optionen zu einem Ausübungspreis von $1,04 (gewährt am 01.10.2025) und 53.316 Optionen zu $1,06 (gewährt am 03.10.2025). Die größere Zuteilung ist eine jährliche Non-Employee-Director-Bewertung gemäß dem 2024 Equity Incentive Plan des Unternehmens und wird am 1. Oktober 2026 vollständig vesten, vorbehaltlich fortgesetzter Dienste. Die kleinere Zuteilung wurde statt $50.000 Bargeldhonorar ausgegeben und vest in vier gleichen vierteljährlichen Raten, endend am 30. September 2026, vorbehaltlich fortgesetzten Dienstes. Beide Optionszuteilungen enthalten eine Beschleunigung bei definiertem Change in Control, sofern die meldende Person unmittelbar vor diesem Ereignis im Dienst bleibt.

Outlook Therapeutics, Inc. مدير Huang Andong تلقّى منحَين من خيارات الأسهم بإجمالي 340,050 خيار: 286,734 خيار بسعر ممارسة $1.04 (ممنوحة في 01/10/2025) و53,316 خيار بسعر $1.06 (ممنوحة في 03/10/2025). المنحة الأكبر هي مكافأة سنوية لمدير غير موظف بموجب خطة حوافز رأس المال 2024 للشركة وتكتمل مطالبته بالاستحقاق في 1 أكتوبر 2026، رهناً ببقاء الخدمة المستمر. المنحة الأصغر أصدرت بدلاً من $50,000 من أتعاب نقدية وتتحقق على أربع أقساط ربع-سنوية متساوية، وتنتهي في 30 سبتمبر 2026، رهناً بخدمة مستمرة. كلا منحه الخيارين يتضمن تسريعاً عند حدوث تغيير السيطرة المحدد إذا بقي الشخص المبلغ في الخدمة فوراً قبل ذلك الحدث.

Outlook Therapeutics, Inc. 董事 Huang Andong 收到两笔股票期权授予,总计 340,050 份期权:286,734 份期权,行权价为 $1.04(授予日期为 2025-10-01),以及 53,316 份期权,行权价为 $1.06(授予日期为 2025-10-03)。较大的一笔授予是公司 2024 Equity Incentive Plan 下的年度非员工董事奖励,自 2026-10-01 起完全归属,前提是持续服务。较小的授予以替代 $50,000 的现金费用发行,按四个等额季度分期归属,结束于 2026-09-30,前提是持续服务。两项期权授予均包含在发生定义的 控制权变更(Change in Control) 时的加速归属,如果报告人于事件发生前仍在任职。

Positive
  • 340,050 total options align director compensation with shareholder interests
  • Fee deferral: $50,000 cash fees converted to equity, conserving cash
  • Grants issued under the 2024 Equity Incentive Plan, indicating formal governance process
Negative
  • Potential future dilution of 340,050 shares if all options are exercised
  • Majority of options vest over ~1 year, delaying immediate alignment with shareholders until Sept–Oct 2026

Insights

Director received standard equity compensation with multi-year vesting and change-in-control acceleration.

The filing shows a total of 340,050 options granted to a director under the 2024 Equity Incentive Plan, split between an annual grant and a fee-for-equity award. The grants have structured vesting through Q3–Q4 2026, tying value realization to continued service.

This structure aligns director pay with shareholder-aligned incentives while including Change in Control acceleration clauses; the document explicitly states the acceleration applies only if the director provides continuous service immediately before such an event.

Outlook Therapeutics, Inc. direttore Huang Andong ha ricevuto due assegnazioni di stock option per un totale di 340.050 opzioni: 286.734 opzioni a un prezzo di esercizio di $1,04 (concesse il 01/10/2025) e 53.316 opzioni a $1,06 (concesse il 03/10/2025). La concessione maggiore è un premio annuale per direttore non dipendente ai sensi del piano azioni 2024 Equity Incentive Plan dell'azienda e si matura integralmente il 1 ottobre 2026, soggetto al servizio continuo. La concessione minore è stata emessa in sostituzione di $50.000 di compensi in contanti e matura in quattro rate trimestrali uguali, terminando il 30 settembre 2026, soggetto al servizio continuo. Entrambe le concessioni di opzioni includono accelerazione in caso di Cambio di Controllo definito se la persona che riferisce rimane in servizio immediatamente prima di tale evento.

Outlook Therapeutics, Inc. director Huang Andong recibió dos concesiones de opciones sobre acciones por un total de 340.050 opciones: 286.734 opciones a un precio de ejercicio de $1,04 (otorgadas el 01/10/2025) y 53.316 opciones a $1,06 (otorgadas el 03/10/2025). La concesión mayor es un premio anual para director no empleado bajo el 2024 Equity Incentive Plan de la empresa y se consolida por completo el 1 de octubre de 2026, sujeto a servicio continuo. La concesión menor fue emitida en sustitución de $50,000 en honorarios en efectivo y se consolida en cuatro cuotas trimestrales iguales, terminando el 30 de septiembre de 2026, sujeto a servicio continuo. Ambas concesiones de opciones incluyen aceleración ante un Cambio de Control definido si la persona que presenta el informe permanece en servicio inmediatamente antes de ese evento.

Outlook Therapeutics, Inc. 이사 Huang Andong은 총 340,050 주의 주식매수선택권을 받았으며, 그 중 286,734주는 실행가격 $1.04로, 2025-10-01에 수여되었습니다. 나머지 53,316주는 $1.06의 가격으로 2025-10-03에 수여되었습니다. 더 큰 수여는 회사의 2024 Equity Incentive Plan에 따른 연간 비근로 이사 보상에 해당하며, 지속적 서비스가 전제될 때 2026-10-01에 완전히 귀속됩니다. 소규모 수여는 현금 수수료 $50,000를 대신하여 발행되었고, 4개 분기 동안 매월 같은 비율로 귀속되며 2026-09-30에 종료됩니다. 두 주식매수선택권 모두 정의된 지배권 변화(Change in Control)가 발생할 경우, 해당 사건 직전까지 보고자가 재직 중이면 가속 귀속이 적용됩니다.

Outlook Therapeutics, Inc. directeur Huang Andong a reçu deux attributions d'options d'achat d'actions pour un total de 340.050 options: 286.734 options à un prix d'exercice de $1,04 (octroyées le 01/10/2025) et 53.316 options à $1,06 (octroyées le 03/10/2025). La plus grande attribution est une récompense annuelle pour directeur non salarié dans le cadre du Plan d'incitation en actions 2024 de l'entreprise et se consolide entièrement le 1er octobre 2026, sous réserve d'un service continu. La plus petite attribution a été émise en lieu et place de $50.000 de frais en espèces et se consolide en quatre versements trimestriels égaux, se terminant le 30 septembre 2026, sous réserve d'un service continu. Les deux attributions d'options prévoient une accélération en cas de changement de contrôle défini si la personne faisant rapport reste en poste immédiatement avant cet événement.

Outlook Therapeutics, Inc. Vorstand Huang Andong erhielt zwei Aktienoptionszuteilungen insgesamt 340.050 Optionen: 286.734 Optionen zu einem Ausübungspreis von $1,04 (gewährt am 01.10.2025) und 53.316 Optionen zu $1,06 (gewährt am 03.10.2025). Die größere Zuteilung ist eine jährliche Non-Employee-Director-Bewertung gemäß dem 2024 Equity Incentive Plan des Unternehmens und wird am 1. Oktober 2026 vollständig vesten, vorbehaltlich fortgesetzter Dienste. Die kleinere Zuteilung wurde statt $50.000 Bargeldhonorar ausgegeben und vest in vier gleichen vierteljährlichen Raten, endend am 30. September 2026, vorbehaltlich fortgesetzten Dienstes. Beide Optionszuteilungen enthalten eine Beschleunigung bei definiertem Change in Control, sofern die meldende Person unmittelbar vor diesem Ereignis im Dienst bleibt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Huang Andong

(Last) (First) (Middle)
C/O OUTLOOK THERAPEUTICS, INC.
111 S. WOOD AVE, UNIT #100

(Street)
ISELIN NJ 08830

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.04 10/01/2025 A 286,734 (1) 10/01/2035 Common Stock 286,734 $0 286,734 D
Stock Option (Right to Buy) $1.06 10/03/2025 A 53,316 (2) 10/03/2035 Common Stock 53,316 $0 53,316 D
Explanation of Responses:
1. This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
2. The options were granted under the 2024 Plan in lieu of $50,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
/s/Lawrence A. Kenyon, Attorney-in-Fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What options did Outlook Therapeutics (OTLK) director receive?

Director Huang Andong was granted 286,734 options at $1.04 (10/01/2025) and 53,316 options at $1.06 (10/03/2025), totaling 340,050 options.

When do the options vest for OTLK director grants?

The 286,734 option grant vests in full on October 1, 2026; the 53,316 option grant vests in four equal quarterly installments and is fully vested on September 30, 2026, subject to continuous service.

Were any cash fees converted to equity for this OTLK filing?

Yes. $50,000 of cash fees were paid in the form of 53,316 options granted under the 2024 Plan.

Do the options include change-in-control provisions?

Yes. Both option grants include acceleration of vesting upon a defined Change in Control, subject to continuous service immediately prior to such event.

Who filed the Form 4 on behalf of the reporting person?

The Form 4 was signed by Lawrence A. Kenyon, Attorney-in-Fact on behalf of the reporting person, dated 10/03/2025.
Outlook Therapeutics Inc

NASDAQ:OTLK

OTLK Rankings

OTLK Latest News

OTLK Latest SEC Filings

OTLK Stock Data

47.53M
28.25M
36.39%
20.54%
15.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
ISELIN